Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.64 |
| ▸ | EGFR | P00533 | 7/20 | 0.64 |
| ▸ | KIT | P10721 | 6/20 | 0.61 |
| ▸ | ABL1 | P00519 | 4/20 | 0.57 |
| ▸ | BCR | P11274 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879660 | 0.95 | EGFR (0.58) | BRAFEGFRKITABL1BCR | |
| SCHEMBL4879698 | 0.92 | BRAF (0.65) | BRAFEGFRKITABL1BCR | |
| SCHEMBL14086128 | 0.90 | EGFR (0.52) | BRAFEGFRKITABL1BCR | |
| SCHEMBL4869570 | 0.87 | MAPK14 (0.60) | BRAFEGFRABL1BCR | |
| SCHEMBL14086424 | 0.85 | HTT (0.47) | BRAFEGFRKITABL1BCR | |
| SCHEMBL4906449 | 0.84 | BRAF (0.67) | BRAFEGFRKITABL1BCR | |
| SCHEMBL4877719 | 0.82 | RAF1 (0.55) | BRAF | |
| SCHEMBL14086313 | 0.82 | EGFR (0.54) | BRAFEGFRKITABL1BCR | |
| SCHEMBL4879633 | 0.81 | BRAF (0.53) | BRAFABL1KDR | |
| SCHEMBL31620774 | 0.81 | BRAF (0.69) | BRAFEGFRKITABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423038-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (A DELAWARE LIMITED LIABILITY CORPORATION) (BM) | 2008-09-09 | — | — | US | claimed |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | IRM LLC (BM) | 2008-05-15 | — | — | US | claimed |
| CN-101031568-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-09-05 | — | — | CN | claimed |
| EP-1765820-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-28 | — | — | EP | claimed |
| WO-2006002367-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-05 | — | — | WO | claimed |
| US-7423038-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (A DELAWARE LIMITED LIABILITY CORPORATION) (BM) | 2008-09-09 | — | — | US | disclosed |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | IRM LLC (BM) | 2008-05-15 | — | — | US | disclosed |
| CN-101031568-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-09-05 | — | — | CN | disclosed |
| EP-1765820-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002367-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | LCK, FRK, FYN | BRAF 31/4885EGFR 254/4885KIT 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.